Technology

**TCH-020** IMPROVING EFFICIENCY IN ELASTOMERIC PUMP FILLING USING DIANA ONCO PLUS, A SEMI-AUTOMATED DEVICE

doi:10.1136/ehjpharm-2013-000276.211


**Background** La Fe Universitario y Politécnico Hospital is a tertiary-care hospital with approximately 1000 beds serving a population of 210,000 people. The pharmacy department owns 4 vertical laminar flow hoods where more than 35,000 chemotherapy treatments, including the filling of 800 elastomeric pumps, are prepared per year.

**Purpose** To compare both the time spent and the accuracy in the filling of elastomeric pumps (EPs) with fluorouracil by two different methods: DIANA ONCO-PLUS, a semi-automated compounding system (IUC Medical Europe), and the normal manual method used in the hospital’s Chemotherapy Unit (CU). The secondary endpoint was to assess user satisfaction with the two methods.

**Materials and Methods** For 4 consecutive weeks, EPs were filled by trained nurses two days per week. The first day DIANA ONCO-PLUS was used and the second day the EPs were filled manually. To avoid bias, every week a different nurse filled the EPs using both methods. Filling time was measured by a different nurse using a conventional chronograph and the accuracy was evaluated by weight of EP (before and after filling). Nurses’ satisfaction was assessed by a questionnaire.

**Results** The filling of sixty-five EPs was evaluated. The filling mean time was 4.25 min with the manual method and 3.84 min with DIANA ONCO-PLUS (p = 0.008). If pure is considered, the mean time was 6.63 min and 5.52 min respectively (p < 0.001). The mean relative error in the filling was 0.735% in manual method and 0.314% in DIANA method (p = 0.006) without any clinical relevance. There was no user-related variability. Nurses were very satisfied using DIANA for filling EP. They considered DIANA more comfortable and safe.

**Conclusions** DIANA ONCO-PLUS is a more accurate and efficient method to fill EPs than the manual method. The differences found were user-independent.

**Acknowledgements** The authors thank the Pharmacy Department of HUF La Fe, Nagore Castro, Loreto Gómez (Hospira PFH SL) and Roberto Zambrano (IUC Medical) for their collaboration in this study.

No conflict of interest.

**TCH-021** INCORPORATION OF IL28B POLYMORPHISM DETERMINATION INTO THE SERVICES PORTFOLIO OF THE PHARMACY DEPARTMENT AND RESULTS OBTAINED

doi:10.1136/ehjpharm-2013-000276.212

N Martinez Casanova, B Cancela Díez, C García Collado, E Puerta García, FJ Casado de Aréuez, MA Calleja Hernández. Hospital Universitario Virgen de las Nieves, Pharmacy, Granada, Spain

**Background** Recent marketing authorizations for the first protease inhibitors for hepatitis C virus (HCV) have changed the management of chronic hepatitis C patients. However, it should be noted that the cost, number as well as the severity of adverse effects will increase. It is therefore reasonable to adopt criteria to ensure maximum efficiency and patient safety. IL-28B polymorphism is one of the factors associated with the treatment outcome and has been closely linked to interferon response.

**Purpose** To describe the implementation of the determination of the IL-28B polymorphism, rs12979860, and the results obtained, in order to personalise the treatment in HCV mono-infected patients in a tertiary hospital.

**Materials and Methods** We designed a standard form for HCV patients starting treatment with protease inhibitors. It includes several items that require clinical evaluation: viral load, HCV genotype, FibroScan and/or liver biopsy, response to previous treatment and polymorphism of the IL-28B genotype. Homozygous CC is the favourable genotype, predicting a good response. CT and TT genotypes are considered unfavourable.

The test was conducted in the pharmacogenetics area of the pharmacy department. To calculate the response time, we considered how long it takes to get the different responses.

The results were added to the hospital’s electronic medical records programme for easy reference online.

**Results** A total of 26 genotypes was determined, of which 11 (42%) were requested by the department of infectious diseases (56% co-infected), 10 (38%) by the hepatology department and 5 (18%) by an external department. Results 15 (58%) were CT, 8 (31%) CC and 3 (11%) TT. 100% of patients had a score of FibroScan > 9.5 kPascal. The response for the tests was on average 3 to 7 days, with the limiting factor the sequencer availability.

**Conclusions** IL28B determination has been added to the hospital’s services portfolio as a clinical assessment tool for the treatment of hepatitis C, with a response time of 3–7 days.

No conflict of interest.

**TCH-022** INTRADIALYTIC CALCIFPHYLAXIS IN RENAL PATIENTS. DEVELOPMENT OF AN INJECTABLE SOLUTION OF 25% SODIUM THIOSULFATE FOR TREATMENT

doi:10.1136/ehjpharm-2013-000276.213

C Gómez Peña, S Ruiz Fuentes, C García Fernandez, S Belda Ruzanaza, C Fernandez Lopez, C Medarde Caballero, A Caballero Romero, D Blanquez Martinez. Hospital San Cecilio, Farmacia Hospitalaria, Granada, Spain

**Background** Calciphylaxis (calcific uremic arteriolopathy) is a cutaneous ulceration of the skin caused by the disseminated calcification of the subcutaneous tissue and small arteries as a consequence of hyperparathyroidism in uraemic patients.

**Purpose** To describe the method of preparation and checking of an injectable solution of 25% sodium thiosulfate for the treatment of intradialytic calciphylaxis in renal patients.

**Materials and Methods** Sodium thiosulfate is an antioxidant, vasodilator and calcium chelator. The preparation process for the solution of 25% sodium thiosulfate is: Ingredients: Sodium thiosulfate pentahydrate: 25 g, water for injection (WFI): qs 100 ml. Preparation: Weigh the amount of sodium thiosulfate in a sterile beaker. Then, working in a horizontal laminar flow hood, boil WFI to eliminate CO2. Dissolve the thiosulfate in about 80 ml of boiled water. Check that the pH of the solution is between 6 and 9.5, if it is not, adjust with HCl or NaOH. Flush into a 100 ml volumetric flask and make up to volume. Filter with a double 0.22 micron filter. Finally pack with 50 ml syringe into a sterile glass bottle and label.

**Results** The result is a solution of 100 ml of 25% sodium thiosulfate, transparent, sterile and stable for 30 days in refrigerator. For QC a visual particulate sterility cheque is performed by sowing in aerobic and anaerobic cultures and a bubble point test to verify the integrity of the phials.

**Conclusions** Proper preparation and checking of the 25% solution of sodium thiosulfate has guaranteed its parenteral administration is safe. The treatment is effective and well tolerated, helping patients and improving their quality of life.

No conflict of interest.